EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

Takafumi Yanagisawa, Akihiro Matsukawa, Paweł Rajwa, Marcin Miszczyk, Tamás Fazekas, Benjamin Pradere, Keiichiro Miyajima, Yuki Enei, Angelo Cormio, Alessandro Dematteis, Timo Soeterik, Atsuya Okada und 5 weitere

Prostate Cancer and Prostatic Diseases · 2026-06 · 29 (2) · 258-270

DOI: 10.1038/s41391-025-01034-y ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Prostate Cancer and Prostatic Diseases, online erschienen am 08.10.2025. Verfasst von Takafumi Yanagisawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Glutamate Carboxypeptidase II, Antigens, Surface, Radiopharmaceuticals. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is a widely accepted treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, synthesized evidence regarding potential prognostic factors for oncologic outcomes in patients treated with PSMA-RLT is lacking. We aimed to synthesize prognosticators of oncologic outcomes in patients with mCRPC treated with PSMA-RLT.

Methods

PubMed®, Web of Science™, and Embase® databases were systemically searched in March 2025 for studies. Eligible studies investigated pretreatment clinical, hematologic, or radiographical prognostic factors for oncologic outcomes, such as progression-free (PFS) or overall survivals (OS) in patients with mCRPC treated with PSMA-RLT. Only parameters assessed through multivariable analysis adjusting for potential confounders were synthesized. ( CRD42024598718 )

Results

A total of 39 studies ( n = 4819) were included in the systematic review and 32 studies ( n = 3038) were included in the meta-analysis. Prior chemotherapy (pooled HR: 1.43, 95%CI: 1.10–1.85), visceral metastases (pooled HR: 1.41, 95%CI: 1.05–1.89), and liver metastasis (pooled HR: 1.75, 95%CI: 1.37–2.25) were associated with worse PFS. Poor performance status (PS) (pooled HR: 1.99, 95%CI: 1.45–2.74), prior chemotherapy (pooled HR: 1.39, 95%CI: 1.19–1.63), visceral metastasis (pooled HR: 1.65, 95%CI: 1.33–2.05), bone metastasis (pooled HR: 2.09, 95%CI: 1.39–3.13), liver metastasis (pooled HR: 2.15, 95%CI: 1.84–2.50), and lower pretreatment hemoglobin levels (pooled HR: 1.25, 95%CI: 1.09–1.43) were associated with poorer OS. Higher pretreatment SUV mean was associated with improved OS benefit (pooled HR: 0.91, 95%CI: 0.85–0.97). PSA decline after treatment initiation, particularly ≥50%, was associated with improved PFS and OS.

Conclusions

Prior chemotherapy use and location of metastases influence the prognosis of patients with mCRPC treated with PSMA-RLT. A higher pre-treatment SUV mean is predictive of better PSMA-RLT efficacy, and a greater PSA 'response is associated with improved survival outcomes. These findings may help guide clinical decision-making regarding PSMA-RLT and support prognostication of its oncological benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantGlutamate Carboxypeptidase IIAntigens, SurfaceRadiopharmaceuticalsHumansMalePrognosis

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, SurfaceRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Theranostics Yokohama, Yokohama, Japan.
  • Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.
  • Department of Urology, Semmelweis University, Budapest, Hungary.

Zitieren

APA

Yanagisawa, T., Matsukawa, A., Rajwa, P., Miszczyk, M., Fazekas, T., Pradere, B., Miyajima, K., Enei, Y., Cormio, A., Dematteis, A., Soeterik, T., Okada, A., Kuruma, H., Lenzo, N., Shariat, S. F., Miki, K., & Kimura, T. (2026). Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 29(2), 258-270. https://doi.org/10.1038/s41391-025-01034-y

Vancouver

Yanagisawa T, Matsukawa A, Rajwa P, Miszczyk M, Fazekas T, Pradere B, et al. Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 2026;29(2):258-270. doi:10.1038/s41391-025-01034-y

BibTeX
@article{Yanagisawa2026,
  author = {Yanagisawa, Takafumi and Matsukawa, Akihiro and Rajwa, Paweł and Miszczyk, Marcin and Fazekas, Tamás and Pradere, Benjamin and Miyajima, Keiichiro and Enei, Yuki and Cormio, Angelo and Dematteis, Alessandro and Soeterik, Timo and Okada, Atsuya and Kuruma, Hidetoshi and Lenzo, Nat and Shariat, Shahrokh F and Miki, Kenta and Kimura, Takahiro},
  title = {Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis},
  journal = {Prostate Cancer and Prostatic Diseases},
  year = {2026},
  volume = {29},
  number = {2},
  pages = {258--270},
  doi = {10.1038/s41391-025-01034-y}
}
Kostenlos starten →